Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 15/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | CTSG | P08311 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13931830 | 0.83 | CMA1 (0.43) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL8289102 | 0.83 | CMA1 (0.70) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL10197824 | 0.82 | CMA1 (0.43) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL10197820 | 0.80 | CMA1 (0.52) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL13490146 | 0.73 | CMA1 (0.39) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL12314971 | 0.71 | CMA1 (0.56) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL12314964 | 0.71 | CMA1 (0.50) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL12314988 | 0.70 | CMA1 (0.50) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL20769662 | 0.70 | KEAP1 (0.52) | CMA1PRSS1PRSS2CTSGPRSS3 | |
| SCHEMBL7476503 | 0.68 | CYP2A6 (0.59) | CMA1PRSS1PRSS2CTSGPRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | HAWKINS MICHAEL J | 2010-02-25 | — | — | US | disclosed |
| US-7459444-B2 | Inhibitors of chymase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048513-A1 | Novel inhibitors of chymase | CMA1, SERPINB1, TPSAB1 | CMA1 1/4885PRSS1 5/4885PRSS2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.